At a glance
Three preclinical papers examine the named inhibitor, including a diet-controlled mouse experiment. None is a human trial or a validation of the listed capsule or vial.
Identity & scope
5-amino-1-methylquinolinium is a small molecule, not a peptide. The exact counterion and formulation of a supplied product remain separate specification questions. The catalogue label 5 Amino 1 is not automatically treated as the same compound.
What the research shows
- The earlier experiments connect NNMT inhibition to changes in cultured adipocytes and reduced adiposity in diet-induced-obese mice [1].
- A later mouse experiment reports changes in fat accumulation, glucose handling and liver pathology over 28 days [2].
Critical interpretation
Less weight gain is a different outcome from weight loss
The 2024 study continued an obesogenic diet. Its principal weight finding was attenuation of further gain, which should not be retold as demonstrated weight loss. The diet-switch experiment asked a different question, whether adding inhibition improved an already changed dietary environment. Those designs help explain why seemingly similar headlines describe different biological comparisons. The latter also measured lean mass relative to body weight: losing fat can improve that ratio without creating new muscle. Neither model establishes a treatment effect in people. [2] [3]
A probe compound and a clinical candidate are different evidence stages
The full-text discussion of the 2024 paper acknowledges ongoing optimisation addressing mouse-specific clearance and activity against MAO-A. That makes an unqualified claim of complete selectivity inappropriate. The earlier cell work is useful target-characterisation evidence, but it cannot resolve exposure and off-target behaviour throughout an organism. Across this selected set, investigators and developer relationships overlap, so several publications should not automatically be counted as independent replication. The next translational questions concern reproducibility, pharmacology and safety before any human-outcome claim. [2] [1] [3]
Limitations & uncertainties
- Animal metabolic responses do not establish human efficacy, exposure, long-term safety or a clinical formulation.
- Independent replication and translation to humans remain important gaps. This selected review did not identify a human efficacy trial.
Open research questions
- Do independently replicated human studies confirm the preclinical metabolic findings?
- How do chemical form, exposure and off-target activity affect the interpretation of NNMT inhibition?
Selected papers & source records
Download bibliography1. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (opens in a new tab)
Neelakantan H, Vance V, Wetzel MD, et al. (2018). Biochemical Pharmacology. DOI: 10.1016/j.bcp.2017.11.007 (opens in a new tab) · PMID 29155147
- Design & population
- Cell-based inhibitor characterization followed by experiments in diet-induced-obese mice.
- What the study found
- The researchers reported less lipid accumulation in cultured adipocytes and reduced body weight and adipose mass in treated mice.
- Limits on interpretation
- Short preclinical experiments cannot establish human weight loss or long-term safety. Target-level observations should not be assigned to every NNMT inhibitor.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
2. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (opens in a new tab)
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H (2024). Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.15879 (opens in a new tab) · PMID 39161060
- Design & population
- 28-day vehicle-controlled study in diet-induced-obese mice, with pharmacokinetic and tissue-distribution experiments.
- What the study found
- Treatment limited fat and weight gain and improved several glucose, insulin and liver measurements in this model.
- Limits on interpretation
- Mouse findings, not human outcomes. Several authors disclosed employment or founder relationships with the developer.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
3. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice (opens in a new tab)
Sampson CM, Dimet AL, Neelakantan H, et al. (2021). Scientific Reports. DOI: 10.1038/s41598-021-85051-6 (opens in a new tab) · PMID 33707534
- Design & population
- Diet-induced-obese mice underwent a diet switch, with or without the named NNMT inhibitor; body composition and liver measurements were followed.
- What the study found
- The combination produced larger fat and weight changes than the diet switch alone. Some liver histology comparisons were sensitive to multiple-testing correction.
- Limits on interpretation
- Small mouse groups, dietary co-intervention and developer-linked authorship. A lean-mass ratio is not evidence of muscle growth, and the model did not reproduce advanced fibrotic human liver disease.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Targeted primary-record search and verification of existing references.. Checked 9 November 2026.
Selected cell and mouse metabolic studies of the named compound.
Narrative selection, not a systematic database search or formal risk-of-bias assessment. Selected methods, results, discussion and disclosure sections of the 2021 and 2024 full texts were checked; supplements were not comprehensively appraised.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov 39161060 5 Amino 1MQ
- site.pubmed.ncbi.nlm.nih.gov 5 amino 1MQ 29155147
- site.pubmed.ncbi.nlm.nih.gov 39161060 retraction
- site.pubmed.ncbi.nlm.nih.gov 33707534
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11622326/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7952898/
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. 5-Amino-1MQ: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/5-amino-1mq.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.